Lars Kuepfer

This study uses high-throughput PBK modelling to predict systemic pharmacokinetics from dermal exposure using in silico data, achieving reasonable accuracy for key metrics.

Dividing Cmax by lowest in vitro toxicity potency separates drugs by liver-injury (DILI) risk, AUC up to 96%; PBK-predicted Cmax without clinical data reaches 91%.

The paper develops a physiologically-based model of bile acid metabolism in humans to analyze how disease-related changes affect bile acid composition along the gut-liver-axis.

This paper develops a method to classify chemicals by Potential Systemic Availability (PSA) concern using physiologically based kinetic modeling and evaluates its alignment with expert judgment.

This study evaluates high-throughput PBK modelling strategies for predicting human intravenous and oral pharmacokinetics using in vitro and in silico data.

The paper identifies natural compounds that mimic dasatinib's senotherapeutic effects using gene expression data, highlighting potential alternatives for senolytic therapy.

This study develops a physiologically-based model of bile acid metabolism in mice to understand its dynamics and implications for disease.

The paper develops a physiology-based model of bile acid metabolism to predict drug-induced liver injury risk and genetic susceptibility.